K. Rezvani

M. Guindani, K. Rezvani, R. Champlin, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

D. Douek, J. Brenchley, K. Rezvani, 2003, Blood.

PR1 vaccination in myeloid malignancies

K. Rezvani, 2008, Expert review of vaccines.

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia

A. Ferrando, A. Haman, T. Hoang, 2022, Nature Communications.

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.

K. Rezvani, D. Marin, J. Goldman, 2010, Blood.

Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial.

K. Rezvani, D. Marin, E. Shpall, 2021, Transplantation and cellular therapy.

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation

P. Thall, K. Rezvani, S. Parmar, 2022, Bone Marrow Transplantation.

Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2

L. Bashoura, K. Rezvani, E. Shpall, 2021, Frontiers in Oncology.

THE EMERGING ROLE OF TARGETED THERAPIES AND CELL THERAPY IN TRANSPLANT Next-generationcell therapies: theemergingroleof CAR-NK cells

R. Başar, K. Rezvani, M. Daher, 2020 .

Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer.

K. Rezvani, M. Daher, 2020, Cancer discovery.

A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.

R. Başar, K. Rezvani, D. Marin, 2017, Blood.

Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation

K. Rezvani, E. Shpall, U. Popat, 2020, Haematologica.

Cancer vaccines and T cell therapy.

R. Advani, H. Kohrt, D. Czerwinski, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Posttransplantation vaccination: concepts today and on the horizon.

K. Rezvani, 2011, Hematology. American Society of Hematology. Education Program.

Editorial: Cellular Therapies in Cancer

K. Rezvani, R. Mehta, H. Rafei, 2019, Front. Immunol..

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

K. Rezvani, D. Marin, J. Goldman, 2011, Haematologica.

Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation.

S. Brett, K. Rezvani, D. Marin, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A robust, good manufacturing practice-compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy.

R. Başar, K. Rezvani, E. Shpall, 2016, Cytotherapy.

elastase diminished sensitivity to the antiproliferative effects of neutrophil Clonal dominance of chronic myelogenous leukemia is associated with

K. Rezvani, K. Keyvanfar, N. Hensel, 2013 .

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

K. Rezvani, D. Marin, J. Goldman, 2008, Blood.

2 prior lines of TKI therapy failed patients with chronic myeloid leukemia in chronic phase who have Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in

K. Rezvani, J. Goldman, L. Foroni, 2013 .

Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.

D. Douek, K. Rezvani, K. Keyvanfar, 2007, Blood.

Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide.

K. Rezvani, D. Marin, E. Shpall, 2022, Transplantation and cellular therapy.

Evidence of robust memory T‐cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)

K. Rezvani, C. Harrison, D. Mclornan, 2021, British journal of haematology.

The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia

Daniel Patrick Smith, N. Ajami, J. Petrosino, 2016, Cancer.

Clinical and Biological Predictors of Outcome Following Relapse of Chronic Myeloid Leukemia after Allogeneic Stem Cell Transplantation

K. Rezvani, P. Muranski, K. Keyvanfar, 2014, Bone marrow transplantation.

The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.

K. Rezvani, J. Melenhorst, A. Barrett, 2005, Blood.

Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients

K. Rezvani, D. Marin, E. Shpall, 2020, Transplant infectious disease : an official journal of the Transplantation Society.

In vitro Induction of Myeloid Leukemia–Specific CD4 and CD8 T Cells by CD40 Ligand – Activated B Cells Gene Modified to Express Primary Granule Proteins

D. Douek, K. Rezvani, S. Kajigaya, 2005, Clinical Cancer Research.

Mycophenolate Mofetil: A Friend or a Foe with PTCy and Tacrolimus Prophylaxis in HLA-Matched donors?

K. Rezvani, R. Jenq, D. Marin, 2022, Transplantation and cellular therapy.

Reconstitution of FOXP 3 regulatory T cells ( Tregs ) after CD 25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease

K. Rezvani, A. Barrett, V. Ghetie, 2007 .

Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

K. Rezvani, A. Barrett, V. Ghetie, 2007, Blood.

IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

R. Başar, K. Rezvani, D. Marin, 2016, Blood.

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.

M. Andreeff, P. Fox, K. Rezvani, 2015, Blood.

Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment.

K. Rezvani, S. Parmar, E. Shpall, 2014, Cytotherapy.

Characterizing metabolism from bulk and single-cell RNA-seq data using METAFlux

K. Rezvani, V. Mohanty, Ken Chen, 2022, bioRxiv.

Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease

R. Başar, K. Rezvani, D. Marin, 2018, Front. Immunol..

Better allele-level matching improves transplant-related mortality after double cord blood transplantation

K. Rezvani, D. Marin, S. Parmar, 2015, Haematologica.

Natural killer cells in antitumour adoptive cell immunotherapy

Tamara J Laskowski, K. Rezvani, Alexander Biederstädt, 2022, Nature reviews. Cancer.

Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance

K. Rezvani, E. Shpall, R. Orlowski, 2021, Leukemia & lymphoma.

Opportunities and limitations of NK cells as adoptive therapy for malignant disease

K. Rezvani, J. Barrett, James O. J. Davies, 2014 .

The role of the immune system in myelodysplasia: implications for therapy.

K. Rezvani, E. Sloand, 2008, Seminars in hematology.

before and after stem cell transplantation in healthy individuals and in patients with chronic myelogenous leukemia T cells exist + Functional leukemia-associated antigen-specific memory CD8

D. Douek, J. Brenchley, K. Rezvani, 2009 .

acute lymphoblastic leukemia specific T lymphocytes after allogeneic stem-cell transplantation for − Graft-versus-leukemia effects associated with detectable Wilms tumor

D. Douek, K. Rezvani, K. Keyvanfar, 2007 .

Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity.

D. Douek, J. Brenchley, K. Rezvani, 2007, Cytotherapy.

T-Cell Responses Directed against Multiple HLA-A*0201-Restricted Epitopes Derived from Wilms' Tumor 1 Protein in Patients with Leukemia and Healthy Donors: Identification, Quantification, and Characterization

D. Douek, J. Brenchley, K. Rezvani, 2005, Clinical Cancer Research.

againstMultiple HLA-A * 0201-Restricted Epitopes Derived fromWilms ’ Tumor 1 Protein in Patients with Leukemia and Healthy Donors : Identification , Quantification , and Characterization

D. Douek, J. Brenchley, K. Rezvani, 2005 .

The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide

Z. Estrov, D. Harris, R. Başar, 2018, Front. Immunol..

Identification and in vitro expansion of CD 4 and CD 8 T cells specific for human neutrophil elastase

D. Douek, K. Rezvani, J. Melenhorst, 2004 .

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation

P. Thall, K. Rezvani, S. Parmar, 2022, Bone Marrow Transplantation.

Aurora: a new direction for a new dawn.

K. Rezvani, 2012, Blood.

Natural killer cells in antitumour adoptive cell immunotherapy

Tamara J Laskowski, K. Rezvani, Alexander Biederstädt, 2022, Nature Reviews Cancer.

driven graft-versus-leukemia effects - peptide following allogeneic stem cell transplantation and may improve PR1 chronic myeloid leukemia is associated with improved outcome High PR3 or ELA2 expression by CD34+ cells in advanced-phase

K. Rezvani, A. Barrett, S. Mielke, 2013 .

High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.

K. Rezvani, A. Barrett, J. Goldman, 2007, Blood.

Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.

K. Rezvani, S. Parmar, E. Shpall, 2014, Blood.

Peptide Vaccines for Myeloid Leukemias

K. Rezvani, Pratap Neelakantan, 2013 .

Peptide vaccine therapy for leukemia

K. Rezvani, 2011, International journal of hematology.

The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B acute lymphoblastic leukemia

K. Rezvani, Hao Liu, E. Shpall, 2015, Leukemia.

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma

K. Rezvani, D. Marin, S. Parmar, 2016, Leukemia & lymphoma.

Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials

K. Rezvani, S. Parmar, E. Shpall, 2015, Front. Med..

G‐CSF‐mobilized CD34+ cells cultured in interleukin‐2 and stem cell factor generate a phenotypically novel monocyte

K. Rezvani, K. Keyvanfar, J. Melenhorst, 2004, Journal of leukocyte biology.

malignancies combined PR1 and WT1 peptide vaccination in patients with myeloid Leukemia-associated antigen-specific T-cell responses following

K. Rezvani, A. Barrett, S. Mielke, 2008 .

transplantation for chronic myeloid leukemia polymerase chain reaction predicts outcome after allogeneic stem cell - Early detection of BCR-ABL transcripts by quantitative reverse transcriptase

C. Craddock, K. Rezvani, N. Cross, 2013 .

Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia.

K. Rezvani, D. Marin, E. Shpall, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia

K. Rezvani, D. Marin, H. Kantarjian, 2015 .

Does a rise in the BCR‐ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?

K. Rezvani, D. Marin, J. Goldman, 2009, British journal of haematology.

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'

P. Hwu, K. Rezvani, E. Shpall, 2018, Nature Reviews Clinical Oncology.

Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.

K. Rezvani, D. Marin, J. Goldman, 2010, Blood.

Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects

K. Rezvani, D. Marin, J. Goldman, 2014, British journal of haematology.

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

K. Rezvani, K. Keyvanfar, A. Barrett, 2008 .

need for further investigation into the effects of discontinuing imatinib therapy in those patients who wish to conceive.

K. Rezvani, D. Marin, J. Goldman, 2017 .

without having achieved an optimal response myeloid leukemia who interrupt therapy on account of pregnancy Poor outcome after reintroduction of imatinib in patients with chronic

K. Rezvani, D. Marin, J. Goldman, 2013 .

Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy

K. Rezvani, E. Shpall, R. Champlin, 2022, Frontiers in Immunology.

Low rate of infusional toxicity after expanded cord blood transplantation.

K. Rezvani, P. Hanley, C. Cruz, 2014, Cytotherapy.

Low Rate of Infusional Toxicity following Expanded Cord Blood Transplantation

H. Liu, K. Rezvani, P. Hanley, 2014 .

Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia.

K. Rezvani, K. Keyvanfar, D. Malide, 2007, Blood.

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

J. Koch, R. Başar, K. Rezvani, 2021, Clinical Cancer Research.

Brief report Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

K. Rezvani, D. Marin, J. Goldman, 2011 .

Cord Blood Expansion: A Clinical Advance.

K. Rezvani, E. Shpall, R. Mehta, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deficient CD 4 CD 25 FOXP 3 T regulatory cells in acquired aplastic anemia

K. Rezvani, K. Keyvanfar, D. Malide, 2007 .

Latent cytomegalovirus infection enhances anti‐tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans

K. Rezvani, C. Bollard, R. Simpson, 2016, Clinical and experimental immunology.

Use of Expanded Allogeneic Third Party BK Virus Specific Cytotoxic T Cells to Target Progressive Multifocal Leukoencephalopathy

K. Rezvani, D. Marin, E. Shpall, 2016 .

Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids

K. Rezvani, E. Shpall, N. Jain, 2020, Mayo Clinic Proceedings.

A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

K. Rezvani, A. Barrett, E. Gostick, 2008, Blood.

STAT3: the "Achilles" heel for AML?

K. Rezvani, J. Barrett, 2014, Blood.

Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

K. Rezvani, E. Shpall, Dean Anthony Lee, 2017, Blood.

Mesenchymal stem cell-derived exosomes for clinical use

K. Rezvani, E. Shpall, M. Mendt, 2019, Bone Marrow Transplantation.

SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies

K. Rezvani, E. Shpall, M. Møller, 2022, Frontiers in Immunology.

human neutrophil elastase Identification and in vitro expansion of CD4+ and CD8+ T cells specific for

D. Douek, K. Rezvani, J. Melenhorst, 2013 .

Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment

K. Rezvani, S. Baldari, Ken Chen, 2022, Life Science Alliance.

Human NK Cells Develop an Exhaustion Phenotype During Polar Degranulation at the Aspergillus fumigatus Hyphal Synapse

K. Rezvani, P. Kelleher, T. Sekine, 2018, Front. Immunol..

KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape

Tamara J Laskowski, R. Başar, K. Rezvani, 2022, Nature Medicine.

The evolution of NK cell immunotherapy for hematologic malignancies: A historical and contemporary perspective.

K. Rezvani, M. Daher, 2020, Seminars in hematology.

Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.

K. Rezvani, A. Barrett, R. Childs, 2006, Blood.

Fludarabine with Myeloablative Timed-Sequential Busulfan in Older Patients: Results of a Randomized Phase II Clinical Trial

K. Rezvani, D. Marin, S. Parmar, 2019 .

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

K. Rezvani, D. Marin, S. Parmar, 2018, The Lancet. Haematology.

Long‐term follow‐up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T‐cell chimerism is associated with high relapse risk and inferior survival

F. Stingo, Z. Estrov, K. Rezvani, 2017, British journal of haematology.

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

G. Calin, K. Rezvani, Katrien Van Roosbroeck, 2016, Clinical Cancer Research.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

K. Rezvani, G. Garcia-Manero, Xuelin Huang, 2022, The Lancet. Haematology.

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

M. Konopleva, K. Rezvani, S. Parmar, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome

M. Konopleva, K. Rezvani, H. Kantarjian, 2018, Clinical lymphoma, myeloma & leukemia.

Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.

K. Rezvani, D. Marin, E. Shpall, 2021, Transplantation and cellular therapy.

Lenalidomide Induced Graft Versus Leukemia in a Cll Patient Who Relapsed After Allogeneic Stem Cell Transplantion

K. Rezvani, E. Shpall, M. Keating, 2016 .

Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.

K. Rezvani, E. Shpall, M. Keating, 2014, Clinical lymphoma, myeloma & leukemia.

General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation.

K. Rezvani, S. Parmar, E. Shpall, 2015, Biology of Blood and Marrow Transplantation.

The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.

K. Rezvani, E. Shpall, C. Bollard, 2014, Clinical lymphoma, myeloma & leukemia.

Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies

K. Rezvani, D. Marin, E. Shpall, 2022, Frontiers in Immunology.

EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure.

K. Rezvani, D. Marin, J. Goldman, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Activated B cells suppress T-cell function through metabolic competition

Tamara J Laskowski, J. Wargo, Fang Wang, 2022, Journal for ImmunoTherapy of Cancer.

Results of a 2‐arm, phase 2 clinical trial using post‐transplantation cyclophosphamide for the prevention of graft‐versus‐host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation

K. Rezvani, D. Marin, E. Shpall, 2016, Cancer.

Escalating-Dose HLA-mismatched donor lymphocyte infusion is safe for the treatment of 1 leukaemia relapse following alemtuzumab-based myeloablative allogeneic stem cell 2 transplantation.

D. Slade, K. Rezvani, J. Goldman, 2013 .

Decrease post-transplant relapse using donor-derived expanded NK-cells

K. Rezvani, G. Behbehani, E. Shpall, 2021, Leukemia.

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

K. Rezvani, J. Slopis, E. Shpall, 2018, Nature Reviews Clinical Oncology.

Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis

Hannah C. Beird, N. Ajami, J. Petrosino, 2015, PloS one.

Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection

K. Rezvani, R. Mehta, 2016, Virulence.

Immunotherapy for infectious diseases in haematological immunocompromise

K. Rezvani, D. Armstrong-James, Maria-Teresa Cutino-Moguel, 2017, British journal of haematology.

Next-generation cell therapies: the emerging role of CAR-NK cells.

R. Başar, K. Rezvani, M. Daher, 2020, Hematology. American Society of Hematology. Education Program.

Next-generation cell therapies: the emerging role of CAR-NK cells.

R. Başar, K. Rezvani, M. Daher, 2020, Blood advances.

CAR‐NK cells: the next wave of cellular therapy for cancer

K. Rezvani, M. Daher, Ye Li, 2021, Clinical & translational immunology.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.

P. Thall, R. Başar, K. Rezvani, 2020, The New England journal of medicine.

Engineering Natural Killer Cells for Cancer Immunotherapy.

Katayoun Rezvani, Enli Liu, K. Rezvani, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

Katayoun Rezvani, K. Rezvani, R. Mehta, 2018, Front. Immunol..

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

P. Hwu, K. Rezvani, E. Shpall, 2018, Nature Reviews Clinical Oncology.

Adoptive cell therapy using engineered natural killer cells

K. Rezvani, 2019, Bone Marrow Transplantation.

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

J. Orange, R. Başar, K. Rezvani, 2018, Leukemia.

GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells

R. Başar, K. Rezvani, E. Shpall, 2021, Frontiers in Immunology.

Engineering the next generation of CAR-NK immunotherapies

K. Rezvani, Alexander Biederstädt, 2021, International Journal of Hematology.

Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future

K. Rezvani, E. Shpall, M. Daher, 2023, Stem cells translational medicine.

Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?

K. Rezvani, E. Shpall, D. Hong, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chimeric antigen receptor T‐cell therapy toxicities

K. Rezvani, E. Shpall, Q. Bashir, 2020, British journal of clinical pharmacology.

Patient-reported symptom and functioning status during the first 12 months after CAR T-cell therapy for hematological malignancies.

C. Cleeland, T. Mendoza, K. Rezvani, 2021, Transplantation and cellular therapy.

Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase.

Katayoun Rezvani, Hiroshi Fujiwara, K. Rezvani, 2003, Blood.

New and emerging therapies for acute and chronic graft versus host disease

K. Rezvani, E. Shpall, A. Alousi, 2018, Therapeutic advances in hematology.

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies

K. Rezvani, A. Barrett, S. Mielke, 2011, Haematologica.

NK cell therapy for hematologic malignancies

K. Rezvani, M. Daher, R. Mehta, 2018, International Journal of Hematology.

M. Konopleva, K. Rezvani, E. Shpall, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

B cells and tertiary lymphoid structures promote immunotherapy response

Jeffrey E. Lee, N. Hacohen, Keren Yizhak, 2020, Nature.

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

K. Rezvani, D. Marin, E. Shpall, 2013, Blood.

The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.

K. Rezvani, E. Shpall, J. Westin, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system

K. Rezvani, D. Marin, J. Goldman, 2012, British journal of haematology.

Targeting the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cells.

Fang Wang, Dihua Yu, R. Başar, 2021, The Journal of clinical investigation.

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.

Matthew S. McNeill, Jing Wang, M. Konopleva, 2020, Blood.

Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD

Jing Wang, M. Konopleva, R. Başar, 2021, Frontiers in Immunology.

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

L. Staudt, A. Rosenwald, T. Greiner, 2012, Blood.

Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia

Marcela R. Uribe, R. Srinivasan, K. Rezvani, 2007, Leukemia.

CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma

A. Mackensen, K. Rezvani, E. Obermann, 2007, Clinical Cancer Research.

Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies

G. Marti, W. Wilson, K. Rezvani, 2004, Clinical Cancer Research.

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.

K. Rezvani, D. Marin, J. Goldman, 2010, Blood.

Generation and testing of clinical-grade exosomes for pancreatic cancer.

A. Maitra, R. Kalluri, K. Rezvani, 2018, JCI insight.

Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Katayoun Rezvani, K. Rezvani, M. Daher, 2018, Current opinion in immunology.

Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant

Michael L. Wang, K. Rezvani, E. Shpall, 2022, British journal of haematology.

Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS

B. Dumitriu, K. Rezvani, Xingmin Feng, 2016, British journal of haematology.

CIS checkpoint deletion enhances the fitness of cord blood derived natural killer cells transduced with a chimeric antigen receptor

Matthew S. McNeill, Jing Wang, M. Konopleva, 2020, bioRxiv.

Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.

K. Rezvani, A. Barrett, 2008, Best practice & research. Clinical haematology.

The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer

K. Rezvani, R. Rouce, 2015, Front. Immunol..

Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients

W. Winkelmayer, K. Rezvani, A. Gaber, 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Antibody-Independent Antitumor Effects of Cd32A-Chimeric Receptor T Cells: Implications for Breast Cancer Prognosis and Treatment

K. Rezvani, S. Baldari, Ken Chen, 2021, bioRxiv.

Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer

K. Rezvani, E. Shpall, Shulin Li, 2021, Nature Reviews Clinical Oncology.

intention-to-treat analysis in chronic myeloid leukemia patients Responses to second-line tyrosine kinase inhibitors are durable: an

K. Rezvani, D. Marin, J. Goldman, 2013 .

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Katayoun Rezvani, Letizia Foroni, K. Rezvani, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.

K. Rezvani, D. Marin, E. Shpall, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

K. Rezvani, R. Clark, D. Marin, 2012, Blood.

High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.

K. Rezvani, K. Keyvanfar, A. Barrett, 2006, Blood.

Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.

K. Rezvani, A. Barrett, R. Childs, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of two methodologies for the enrichment of mononuclear cells from thawed cord blood products: The automated Sepax system versus the manual Ficoll method.

Katayoun Rezvani, Frank Flagge, K. Rezvani, 2017, Cytotherapy.

Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy

K. Rezvani, R. Childs, S. Mielke, 2012, Cancer Immunology, Immunotherapy.

Post-Transplantation Cyclophosphamide vs Tacrolimus and Methotrexate Graft-versus-Host Disease Prophylaxis For HLA-Matched Donor Transplantation.

K. Rezvani, E. Shpall, Y. Nieto, 2022, Transplantation and cellular therapy.

T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.

K. Rezvani, A. Barrett, R. Childs, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reconstitution of Lymphocyte Subsets and Outcomes After Matched and Mismatched Hematopoietic Stem-Cell Transplantation

K. Rezvani, E. Shpall, Dean Anthony Lee, 2012 .

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

M. Caligiuri, C. Lengerke, B. Becher, 2018, Nature Medicine.

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis

G. Sauvageau, C. Perreault, K. Rezvani, 2019, British journal of haematology.

Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation.

R. Srinivasan, K. Rezvani, A. Barrett, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA Factors Versus Non-HLA Factors for Haploidentical Donor Selection.

K. Rezvani, D. Marin, E. Shpall, 2022, Transplantation and cellular therapy.

Can we make a better match or mismatch with KIR genotyping?

K. Rezvani, R. Mehta, 2016, Hematology. American Society of Hematology. Education Program.

A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids

K. Rezvani, E. Shpall, Y. Nieto, 2015 .

How I treat high-risk acute myeloid leukemia using pre-emptive adoptive cellular immunotherapy.

K. Rezvani, Alexander Biederstädt, 2022, Blood.

Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

K. Rezvani, A. Barrett, James O. J. Davies, 2014, Cytotherapy.

Translational Mini‐Review Series on Vaccines: Peptide vaccines for myeloid leukaemias

K. Rezvani, A. Barrett, 2007, Clinical and experimental immunology.

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.

K. Rezvani, D. Marin, H. Kantarjian, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

K. Rezvani, A. Barrett, B. Savani, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adoptive cell therapy: Living drugs against cancer

Tamara J Laskowski, K. Rezvani, 2020, The Journal of experimental medicine.

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.

R. Başar, K. Rezvani, D. Marin, 2016, Blood.

Inhibition of the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cells

Dihua Yu, R. Başar, K. Rezvani, 2020, bioRxiv.

Expanded NK cells used for adoptive cell therapy maintain diverse clonality and contain long-lived memory-like NK cell populations

K. Rezvani, Chuanfeng Wu, C. Dunbar, 2022, Molecular therapy oncolytics.

CD34+ cells cultured in stem cell factor and interleukin-2 generate CD56+ cells with antiproliferative effects on tumor cell lines

K. Rezvani, J. Melenhorst, A. Barrett, 2005, Journal of Translational Medicine.

Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy

Tamara J Laskowski, R. Başar, K. Rezvani, 2021, Cell Reports.

A phase two study of high dose blinatumomab in Richter’s syndrome

Naveen Garg, M. Andreeff, R. Başar, 2022, Leukemia.

Plasmacytoma relapses in the absence of systemic progression post‐high‐dose therapy for multiple myeloma

K. Rezvani, S. Basu, E. Terpos, 2005, European Journal of Haematology.

Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Part II: Impact of latent cytomegalovirus infection and catecholamine sensitivity

K. Rezvani, C. Bollard, R. Simpson, 2015, Brain, Behavior, and Immunity.

Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial

G. Fuller, J. Huse, G. Rao, 2020, Clinical Cancer Research.

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

K. Rezvani, D. Marin, H. Kantarjian, 2019, Biology of Blood and Marrow Transplantation.

Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein

K. Rezvani, K. Keyvanfar, A. Barrett, 2010, Leukemia.

Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.

R. Srinivasan, K. Rezvani, A. Barrett, 2005, The Lancet. Oncology.

Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.

A. Dutra, K. Rezvani, P. Muranski, 2015, Stem cell research.

Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.

R. Başar, K. Rezvani, D. Marin, 2021, Blood.

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.

K. Rezvani, E. Shpall, A. Sergeeva, 2016, Cytotherapy.

Neutrophil granule proteins as targets of leukemia-specific immune responses

K. Rezvani, J. Barrett, 2006, Current opinion in hematology.

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

K. Rezvani, D. Marin, S. Parmar, 2017, Blood.

UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.

K. Rezvani, I. Samudio, G. Krystal, 2016, Blood.

Epstein-Barr Virus and B Cells in the Pathogenesis of Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem-Cell Transplantation.

K. Rezvani, R. Champlin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOXP3-Positive Regulatory T-Cells in Acquired Aplastic Anemia.

K. Rezvani, K. Keyvanfar, D. Malide, 2006 .

Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation

R. Başar, K. Rezvani, D. Marin, 2018, Front. Immunol..

Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

P. Thall, R. Başar, K. Rezvani, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis

K. Rezvani, S. Parmar, E. Shpall, 2021, Haematologica.

Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial

M. Konopleva, K. Rezvani, D. Marin, 2021, Blood.

Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

P. Thall, K. Rezvani, D. Marin, 2021, Blood.

Improving outcomes in myeloid leukemia patients: does a new DNA vaccine hold the answer?

K. Rezvani, H. de Lavallade, 2011, Expert review of vaccines.

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

K. Rezvani, R. Clark, D. Marin, 2013, Blood.

Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

P. Thall, K. Rezvani, D. Marin, 2019, Blood.

Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies

K. Rezvani, D. Marin, H. Kantarjian, 2015 .

Minimal Residual Disease Detected By Multiparameter Flow Cytometry and Complex Karyotype Are the Major Prognostic Factors for Relapse after HCT

K. Rezvani, D. Marin, E. Shpall, 2015 .

Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells

K. Rezvani, C. Bollard, R. Simpson, 2014, Brain, Behavior, and Immunity.

Comment on Hossain et al , page 15 STAT 3 : the “ Achilles ” heel for AML ?---------------------------------------------------------------------------------------------------- -

K. Rezvani, J. Barrett, 2013 .

Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking.

K. Rezvani, D. Marin, E. Shpall, 2021, Cytotherapy.

Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.

Katayoun Rezvani, Holger W Auner, K. Rezvani, 2010, Blood.

myeloid leukemia: implications for early intervention strategies Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic

K. Rezvani, D. Marin, J. Goldman, 2013 .

KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma

K. Rezvani, E. Shpall, R. Orlowski, 2022, Bone Marrow Transplantation.

Impact of Donor Age in Haploidentical-PTCy Versus MUD-PTCy HCT in AML patients.

K. Rezvani, D. Marin, E. Shpall, 2023, Transplantation and cellular therapy.

Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS

K. Rezvani, D. Marin, E. Shpall, 2023, American journal of hematology.

Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type

K. Rezvani, D. Marin, E. Shpall, 2023, Blood advances.

Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, K. Rezvani, E. Shpall, 2021, Bone Marrow Transplantation.

Development and validation of a patient‐reported outcome measure to assess symptom burden after chimeric antigen receptor T‐cell therapy

C. Cleeland, T. Mendoza, K. Rezvani, 2023, British journal of haematology.

Anti–miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response

M. Ferracin, G. Calin, R. Başar, 2023, The Journal of clinical investigation.

Immunotherapy: Can we include vaccines with stem-cell transplantation?

K. Rezvani, J. Barrett, 2009, Nature Reviews Clinical Oncology.

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.

R. Hills, K. Rezvani, D. Marin, 2016, Blood.

Graft loss attributed to possible transfusion‐transmitted ehrlichiosis following cord blood stem cell transplant

K. Rezvani, E. Shpall, Micah M. Bhatti, 2018, Transplant infectious disease : an official journal of the Transplantation Society.

Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.

K. Rezvani, S. Parmar, E. Shpall, 2018 .

Reduction in Incidence of Severe Infections by Transplantation of High Doses of Haploidentical T Cells Selectively Depleted of Alloreactive Units

G. Sauvageau, C. Perreault, K. Rezvani, 2011 .

Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease

K. Rezvani, D. Marin, E. Shpall, 2020 .

Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

K. Rezvani, C. Harrison, D. Mclornan, 2020 .

CD40-ligand/interleukin-2 vaccines in chronic lymphocytic leukemia: the impact of vaccine design.

K. Rezvani, 2011, Cytotherapy.

In Vitro Induction of Myeloid Leukemia Specific CD4 and CD8 T-Cells by CD40 Ligand Activated B Cells Gene-Modified to Express Primary Granule Proteins.

D. Douek, K. Rezvani, S. Kajigaya, 2004 .

Abstract CT003: Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma

R. Başar, K. Rezvani, E. Shpall, 2022, Cancer Research.

Role of killer cell immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML).

R. Başar, K. Rezvani, D. Marin, 2019, Journal of Clinical Oncology.

High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients

P. Thall, K. Rezvani, E. Shpall, 2021, Frontiers in Immunology.

Myelodysplasia with Trisomy 8 Is Associated with a Cytotoxic CD8 T Cell Immune Response to Wilms Tumor-1 Protein (WT1).

D. Douek, K. Rezvani, N. Young, 2004 .

PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.

K. Rezvani, E. Shpall, C. Bollard, 2016, Cytotherapy.

High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients

P. Thall, K. Rezvani, E. Shpall, 2021, medRxiv.

Cord blood expansion has arrived.

K. Rezvani, E. Shpall, 2021, Blood.

The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission,

K. Rezvani, D. Marin, J. Goldman, 2011 .

Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering

Tamara J Laskowski, J. Lohr, R. Başar, 2023, Science advances.

Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future

K. Rezvani, E. Shpall, M. Daher, 2023, Stem Cells Translational Medicine.

Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer

K. Rezvani, Ye Li, H. Rafei, 2023, Immunological reviews.

Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation.

G. Calin, M. Hung, A. Caudle, 2023, Cell metabolism.

The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022

P. Ascierto, B. Fox, K. Rezvani, 2023, Journal of Translational Medicine.

for chronic myeloid leukemia patients on long-term therapy Poor adherence is the main reason for loss of CCyR and imatinib failure

K. Rezvani, D. Marin, L. Foroni, 2013 .

Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)

P. Ascierto, T. Kirchhoff, B. Fox, 2023, Journal of Translational Medicine.

Characterizing cancer metabolism from bulk and single-cell RNA-seq data using METAFlux

K. Rezvani, V. Mohanty, Ken Chen, 2023, Nature communications.

Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen

K. Rezvani, D. Marin, E. Shpall, 2019, Blood.

Responses to second-line tyrosine kinase inhibitors are durable : an intention-to-treat analysis in chronic myeloid leukemia patients

K. Rezvani, D. Marin, J. Goldman, 2012 .

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

K. Rezvani, D. Marin, J. Goldman, 2012, Blood.

The TGF-β/SMAD Signaling Pathway As a Mediator of NK Cell Dysfunction and Immune Evasion in Myelodysplastic Syndrome

M. Andreeff, R. Başar, K. Rezvani, 2017 .

Cord Blood NK Cells Engineered to Express a Humanized CD123-Targeted Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia

J. Orange, M. Konopleva, M. Andreeff, 2017 .

Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions

K. Rezvani, E. Shpall, J. Burger, 2015 .

Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway

Z. Estrov, D. Harris, R. Başar, 2018, Leukemia.

Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.

K. Rezvani, D. Marin, S. Parmar, 2017, Blood.

Cancer vaccines and T cell therapy.

R. Advani, H. Kohrt, D. Czerwinski, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia.

K. Rezvani, D. Marin, E. Shpall, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.

R. Başar, K. Rezvani, D. Marin, 2017, Blood.

Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS

B. Dumitriu, K. Rezvani, Xingmin Feng, 2016, British journal of haematology.

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

G. Calin, K. Rezvani, Katrien Van Roosbroeck, 2016, Clinical Cancer Research.

Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

K. Rezvani, E. Shpall, Dean Anthony Lee, 2017, Blood.

K. Rezvani, D. Marin, E. Shpall, 2016, Cancer.

Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study.

K. Rezvani, B. Andersson, B. Valdez, 2024, American journal of hematology.

Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation